Document is current
Any future updates will be listed below
-
Authors
Sheth, Veeral S.
Vujosevic, Stela
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04432831 at ClinicalTrials.govDocuments that mention this clinical trial
Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast
https://doi.org/10.1007/s40123-026-01470-6
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 15 April 2026
Accepted: 22 July 2026
First Online: 20 August 2026
Change Date: 28 August 2026
Change Type: Update
Change Details: The original online version of this article was revised due to incorrect video file placement . Now, it has been updated.
Declarations
Conflict of Interest: Veeral S. Sheth: speaker—Genentech, Inc./Roche; consultant—Alkeus, Apellis, Boehringer Ingelheim, EyePoint, Genentech, Inc., Iveric Bio, Janssen, Kriya, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ollin, Opthea, Regeneron, RevOpsis, Unity, and Vial; contracted research—4DMT, AbbVie, Adverum, Alimera, Ashvattha, Astellas, Aviceda, Chengdu Kanghong, Eluminex, EyeBio, EyePoint, Genentech, Inc., Gyroscope, i-Lumen, Ionis, Iveric Bio, Janssen, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Opthea, Outlook, Oxular, Oxurion, Perfuse, RecensMedical, Regeneron, Regenxbio, Rezolute, Roche, SalutarisMD, SamChungDang, Santen, Smile Biotech, Unity, and Vanotech. Stela Vujosevic: consultant—AbbVie/Allergan, Adverum, Alimera, Apellis, Bayer, Boehringer Ingelheim, Novartis, RetinAI, Roche, and ZEISS.
Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
